Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study

This study was conducted to determine the maximum tolerated dose and dose-limiting toxicity of irinotecan (CPT-11) administered every 3 weeks to adults with progressive malignant glioma who were treated with enzyme-inducing antiepileptic drug (EIAED) therapy, and to compare the pharmacokinetics with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Prados, Michael D., Yung, W.K.A., Jaeckle, Kurt A., Robins, H. Ian, Mehta, Minesh P., Fine, Howard A., Wen, Patrick Y., Cloughesy, Timothy F., Chang, Susan M., Nicholas, M. Kelly, Schiff, David, Greenberg, Harry S., Junck, Larry, Fink, Karen L., Hess, Kenneth R., Kuhn, John
Formato: Artigo
Idioma:Inglês
Publicado em: Duke University Press 2004
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1871968/
https://ncbi.nlm.nih.gov/pubmed/14769140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/S1152851703000292
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados